Oppenheimer assumed coverage of Tarsus Pharmaceuticals (TARS) with an Outperform rating with a price target of $75, up from $72. The firm notes the company reported Q1 2025 topline of $78.3M, beating consensus estimates, with volume of about 72K surpassing guidance. XDEMVY’s momentum remains strong, driven by its growth initiatives. Management highlighted encouraging shifts in prescribing patterns from monthly to weekly prescribing, noting that thousands of target ECPs remain below capacity. Oppenheimer is encouraged by broad commercial, Medicare, and Medicaid coverage. With sales force expansion, coverage, DTC, and evidence generation progressing, plus a strengthened balance sheet, the firm believes XDEMVY’s momentum is well-poised to grow.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Promising Growth Trajectory of Tarsus Pharmaceuticals: Buy Rating Supported by Unique Product Positioning and Strong Market Presence
- Tarsus Pharmaceuticals assumed with a Buy at H.C. Wainwright
- Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
- Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating